Sanofi's vaccine production facility to strengthen Singapore's future pandemic readiness
Add BT as a preferred source
FRENCH healthcare company Sanofi broke ground for a vaccine production facility in Singapore on Wednesday (Apr 20), which is expected to create up to 200 local jobs, while providing greater and flexible vaccine production capacity.
The modular nature of this "evolutive vaccine facility" (EVF) makes it possible to produce 3 to 4 different vaccines simultaneously, in contrast to typical vaccine manufacturing facilities that can only produce 1 type of vaccine at a time.
This will enable more flexible manufacturing of multiple vaccines and biological platforms, including mRNA, enzymes and monoclonal antibodies, the company said in its press statement.
TRENDING NOW
SIA sinks into the red with S$76 million Q1 loss as fuel costs jump
15-month wait-out curb lifted for private property owners buying HDB resale flats
ABSD deadline extended to up to 7 years for developers of large en bloc sites to encourage reuse of land
A ‘shadow bank’ hiding in Singapore’s Little India casts light on financial services gap
